Highlights ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
8.89 ^USD	+1.72%		-5.93%	+62.23%

09/05	ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	30/04	CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	30/04	CI
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03/04	MT
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03/04	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
North American Morning Briefing : Stock Futures -2-	06/03	DJ
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study	26/02	CI
ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA?s Complete Response Letter	20/02	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Ars Pharmaceuticals, Inc. Announces Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology	03/23/03	CI
Top Stories at Midday: Instacart Loses Ground; Ford Averts Canadian Strike; Stellantis Starts Furloughs; Apple, Goldman Explore Trading App	20/23/20	MT
ARS Pharmaceuticals' CRL Announcement a 'Major Blow' to Neffy Approval, Wedbush Says	20/23/20	MT
Rate Hike Pause Hopes Boost Exchange-Traded Funds, Equity Futures Premarket Wednesday	20/23/20	MT
ARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray	20/23/20	DJ
US FDA declines to approve first nasal spray equivalent of EpiPen	20/23/20	RE
ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study	20/23/20	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
ARS Pharmaceuticals Says FDA Extends Target Action Date for Neffy to September	20/23/20	MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Highlights

Filters